Apellis Pharmaceuticals (APLS) Competitors $19.76 +0.41 (+2.10%) Closing price 03:59 PM EasternExtended Trading$19.81 +0.05 (+0.27%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTXShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics BridgeBio Pharma (NASDAQ:BBIO) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Does the media favor BBIO or APLS? In the previous week, BridgeBio Pharma had 14 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 21 mentions for BridgeBio Pharma and 7 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.84 beat BridgeBio Pharma's score of 0.82 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of BBIO or APLS? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is BBIO or APLS more profitable? Apellis Pharmaceuticals has a net margin of -28.83% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-524.25% N/A -94.43% Apellis Pharmaceuticals -28.83%-99.19%-25.35% Which has preferable valuation & earnings, BBIO or APLS? Apellis Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$127.42M70.18-$535.76M-$3.53-13.34Apellis Pharmaceuticals$775.84M3.20-$197.88M-$1.79-11.04 Do analysts recommend BBIO or APLS? BridgeBio Pharma presently has a consensus target price of $61.20, suggesting a potential upside of 29.96%. Apellis Pharmaceuticals has a consensus target price of $39.84, suggesting a potential upside of 101.67%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Which has more risk & volatility, BBIO or APLS? BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. SummaryApellis Pharmaceuticals beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48B$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-11.0420.5028.6419.75Price / Sales3.20267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book10.747.768.235.67Net Income-$197.88M-$55.11M$3.24B$257.98M7 Day Performance2.84%1.03%0.05%0.56%1 Month Performance7.96%8.54%5.65%8.88%1 Year Performance-51.99%-2.26%26.57%14.24% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.2287 of 5 stars$19.76+2.1%$39.84+101.7%-51.6%$2.48B$775.84M-11.04770News CoverageAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.631 of 5 stars$47.69+2.6%$61.20+28.3%+68.7%$9.06B$221.90M-13.51400Analyst ForecastAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.2694 of 5 stars$104.67-0.2%$109.00+4.1%+387.3%$8.91B$42.28M-52.3430Positive NewsAnalyst ForecastHigh Trading VolumeBPMCBlueprint Medicines1.0948 of 5 stars$129.36+0.0%$128.25-0.9%+8.2%$8.35B$508.82M-52.37640Positive NewsHigh Trading VolumeROIVRoivant Sciences2.7913 of 5 stars$11.63+2.4%$16.50+41.9%-1.2%$7.91B$29.05M-46.52860Positive NewsELANElanco Animal Health1.4909 of 5 stars$14.88-0.2%$15.33+3.1%+9.4%$7.39B$4.44B20.109,000RGCRegencell Bioscience0.337 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Positive NewsGap UpLEGNLegend Biotech3.37 of 5 stars$39.44+1.2%$72.70+84.3%-26.7%$7.25B$627.24M-66.852,609Gap UpRVMDRevolution Medicines4.5999 of 5 stars$38.37+0.9%$68.00+77.2%-17.8%$7.15B$11.58M-9.59250Analyst ForecastGRFSGrifols3.5235 of 5 stars$9.72-0.2%$10.30+6.0%+19.7%$6.68B$7.81B8.3123,822News CoverageGap UpTGTXTG Therapeutics3.6141 of 5 stars$38.92+5.0%$43.80+12.5%+78.5%$6.18B$329M162.17290Positive News Related Companies and Tools Related Companies BBIO Alternatives VRNA Alternatives BPMC Alternatives ROIV Alternatives ELAN Alternatives RGC Alternatives LEGN Alternatives RVMD Alternatives GRFS Alternatives TGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
